Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTT-011
- Development stage
- Preclinical
- Lead developer
- Pyrotech Therapeutics
- Modality
- Small Molecules
01
Overview
PTT-011 is an early-stage drug candidate under development by Pyrotech Therapeutics for the treatment of autoimmune diseases. The compound is part of a pipeline focused on the precision modulation of innate immunity and pyroptosis, a form of programmed inflammatory cell death. Pyrotech's research, led by co-founder Dr. Feng Shao, centers on key mediators of these pathways, including the NLRP3 inflammasome and gasdermin-D (GSDMD). While the specific molecular target of PTT-011 has not been publicly disclosed, it is being developed using the company's "Chemical Switches" platform, which identifies small molecules to control innate immune signaling. As of 2024, PTT-011 is in the early discovery phase.
Beyond the preview
Go deeper on PTT-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTT-011.